Alcon AG ALC
SIX · Switzerland · Health Technology
CHF 52.86-1.12 (-2.07%)
Market closed· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
TORONTO, September 28, 2026--Alcon, the global leader in eye care, announces the launch of Systane® PRO Preservative-Free (PF) in Canada.
Alcon has seen its share price grind lower in recent years, which naturally puts a spotlight on whether the current valuation still lines up with what the business earns. For anyone tracking the stock, the core question is whether the recent price level reflects a fair read of Alcon's earnings power. The share price has declined 26.8% over the past 5 years, which puts real pressure on the idea that the current market value is in step with the earnings the company produces. The business model...
Investing.com -- European medtech has had another bruising year, with only Demant and Sonova outperforming the Stoxx 600 in 2026 as the sector’s once-premium valuation continues to de-rate.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.